Voyager Therapeutics Inc (VYGR)
Voyager Therapeutics Inc (NASDAQ-VYGR) is a NASDAQ-listed biotechnology company whose common stock reflects an operating-company equity security. The company is associated with research and development work in neurological and central nervous system disorders, using gene therapy and related platform approaches. Its business is organized around early-stage scientific programs, discovery tools, and collaboration-driven development activities rather than a diversified consumer or industrial model. As common equity, VYGR represents ownership in the company and is not a fund, note, or other pooled investment vehicle. Investors should view it as a healthcare-sector stock tied to biotechnology research and development risk.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-VYGR
|
$3.42
|
9.0% Upside
|
Fair
|
$14.89
|
374.2% Upside
|
Bargain
|
Fair
|
0.0%
|
November 10, 2026
|
1.2x
|
5.5x
|
193.5 M
|
73.536 M
|
14.6%
|
72.2%
|
-2.0
|
112.7%
|
